Skip to main content
SIBNSI-BONE, Inc.Sell5.2·$23.73
SellModerate Confidence
Investment thesis

SI-BONE has posted a perfect 4-quarter earnings beat streak and holds a strong Piotroski score, but quality sits below the engine's floor on a failed Rule of 40 test, the V9 panel hard-blocks on a death cross, and both short interest and insider selling point to bearish positioning.

Thesis pillars

  • Quality Below Floor Rule Of 40 Fail→Stable
  • Death Cross Hard Block→Stable
  • Perfect Earnings Beat Streak→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days

Full reasoning →

Open full analysis

SI-BONE, Inc. (SIBN) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Devices

Sell if holding. Engine safety override at $23.73: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 12%; Below-average business quality.

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the... Read more

$23.73-1.8% A.UpsideScore 5.2/10#40 of 62 Medical Devices
QualityF-score8 / 9FCF yield-0.11%
Stop $22.07Analyst target $23.30(reached)A.R:R -0.1:1
Analyst consensus$26.78+12.8%9 analysts with price targets
$23.73price
$26.78mean
$32

Sell if holding. Engine safety override at $23.73: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 12%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.

Passes 6/9 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 92d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 19, 2026

Recent Developments — SI-BONE, Inc.

Latest item Nov 19, 2026 · Generated 2026-11-22T11:57:10Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Feb 22, 202792d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Target reached (-1.8% upside)
Quality below floor (3.5 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-82.6
Mkt Cap$1.1B
EV/EBITDA-95.9
Profit Mgn-6.2%
ROE-7.7%
Rev Growth14.5%
Beta0.62
DividendNone
Analysts with ratings15

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.22bullish
IV53%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Unprofitable operations — net margin -6.2%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Current Ratio
5.4
Moat
7.2
Piotroski F
8.9
Gross Margin
10.0
Cash-burning: FCF -1% of revenueRule of 40: 14 (fail)Strong Piotroski F-Score: 8/9
GatesA.R:R -0.1=NEGATIVEINSIDER 0.75%=EXTREMEMomentum 5.3<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.3>=4.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 92d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
68 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.07Resistance $25.92

Price Targets

A.Upside-1.8%
A.R:R-0.1:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Target reached (-1.8% upside)
! Quality below floor (3.5 < 4.0)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-02-22 (92d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SIBN stock a buy right now?

Sell if holding. Engine safety override at $23.73: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 12%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $22.07. Score 5.2/10, moderate confidence.

What is the SIBN stock price target?

Analyst target $23.30 reached (−1.8% from $23.73); no take-profit level is published. Prior stop was $22.07. Stop-loss: $22.07.

What are the risks of investing in SIBN?

Target reached (-1.8% upside); Quality below floor (3.5 < 4.0).

Is SIBN overvalued or undervalued?

SI-BONE, Inc. trades at a P/E of N/A (forward -82.6). TrendMatrix value score: 5.2/10. Verdict: Sell.

What do analysts say about SIBN?

15 analysts rate SIBN, with a consensus score of 4.2/5. 9 analysts publish price targets averaging $27.

What does SI-BONE, Inc. do?SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in...

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Related stocks: DCTH (Delcath Systems, Inc.) · PODD (Insulet Corporation) · MASS (908 Devices Inc.) · BVS (Bioventus Inc.) · SENS (Senseonics Holdings, Inc.)
Home › Stocks › SIBN

Latest news

Latest News

Fiscal.ai3d ago
Fiscal.ai12d agoAnalyst
Fiscal.ai15d ago
Fiscal.ai15d ago
Fiscal.ai19d ago
Benzinga19d agoAnalyst
Benzinga19d agoAnalyst
Fiscal.ai19d agoAnalyst
Benzinga19d agoAnalyst
Benzinga20d agoEarnings
Fiscal.ai20d ago
Benzinga20d agoEarnings
Benzinga20d ago
Fiscal.ai23d ago
Fiscal.ai34d ago
Benzinga39d agoAnalyst
Benzinga55d agoFda Decision
Benzinga72d ago
Benzinga110d agoAnalyst
Benzinga110d agoAnalyst
Loading more...